AI Article Synopsis
- Invasive aspergillosis is rare in healthy individuals but is the second most common fungal infection in those with weakened immune systems.
- The occurrence of severe aspergillosis cases has significantly risen over the last 20 years, leading to high rates of illness and death even with antifungal treatments.
- A specific case of an amphotericin B-resistant strain of Aspergillus flavus was successfully treated with caspofungin, highlighting its potential as an effective new antifungal option for invasive aspergillosis.
Article Abstract
Invasive aspergillosis is uncommon in immunocompetent hosts but is the second most common opportunistic fungal infection in immunocompromised patients. There has been a dramatic increase in the incidence of life-threatening aspergillosis during the past 2 decades, and the morbidity and mortality of these infections despite antifungal therapy remain unacceptably high. We describe a patient with amphotericin B-resistant Aspergillus flavus successfully treated with caspofungin, an agent belonging to a new class of antifungal drugs. Caspofungin shows great promise in the treatment of invasive aspergillosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1067/mjd.2002.120627 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!